Quest Diagnostics (DGX) Reports In-Line Q1 EPS; Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Mizuho Securities Raises Price Target on Quest Diagnostics (DGX) Following In-Line 1Q Results
April 21, 2016 2:16 PM EDTMizuho Securities reiterated an Outperform rating on Quest Diagnostics (NYSE: DGX), and raised the price target to $84.00 (from $75.00), following the company's 1Q earnings report. DGX reported an adjusted EPS of $1.12, in-line with consensus estimates.
Analyst Ann Hynes commented, "We are raising our price... More
